Press Releases

Date Title
12/18/24 Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
11/29/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26/24 Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
11/6/24 Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
10/31/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/23/24 Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
9/30/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/30/24 Sarepta Therapeutics anuncia a los destinatarios de las subvenciones de 2024 para LGMD; el programa apoya las pruebas genéticas tempranas y la concientización
9/30/24 Sarepta Therapeutics Announces Recipients of LGMD Grant Awards for 2024; Program Supports Early Genetic Testing and Awareness
9/26/24 Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
9/16/24 Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
9/5/24 Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
9/5/24 Sarepta Therapeutics anuncia los destinatarios de la 7ª edición anual de Route 79, el programa de becas de Duchenne, para el año académico 2024-2025
8/30/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/30/24 Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
8/7/24 Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
7/31/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/29/24 Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
6/28/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/20/24 Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
5/31/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/3/24 Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
5/1/24 Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
4/30/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/24/24 Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
3/29/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19/24 Sarepta Therapeutics anuncia la convocatoria de solicitudes para el Programa de concesión de subvenciones para LGMD 2024
3/19/24 Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
3/4/24 Sarepta Therapeutics to Present at Upcoming Investor Conferences
2/29/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/29/24 Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
2/29/24 Sarepta Therapeutics anuncia convocatoria de solicitudes para el 7.º Route 79 anual, el Programa de Becas de Duchenne
2/28/24 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
2/21/24 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
2/16/24 Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
1/31/24 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/29/24 Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
1/16/24 Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
1/8/24 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
1/2/24 Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference